Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.070
+0.020 (1.90%)
Nov 20, 2025, 9:43 AM EST - Market open
Fate Therapeutics Employees
Fate Therapeutics had 181 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
181
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$39,431
Profits / Employee
-$862,398
Market Cap
123.43M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 181 | 0 | - |
| Dec 31, 2023 | 181 | -370 | -67.15% |
| Dec 31, 2022 | 551 | 102 | 22.72% |
| Dec 31, 2021 | 449 | 170 | 60.93% |
| Dec 31, 2020 | 279 | 101 | 56.74% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
FATE News
- 7 days ago - Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 15 days ago - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 24 days ago - Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy - GlobeNewsWire
- 3 months ago - Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 5 months ago - Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress - GlobeNewsWire
- 6 months ago - Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors - GlobeNewsWire
- 6 months ago - Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress - GlobeNewsWire
- 6 months ago - Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates - GlobeNewsWire